查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1751295

美國馬再生醫學市場規模、佔有率和趨勢分析報告：按產品、應用、最終用途、州和細分市場預測，2025 年至 2030 年

U.S. Equine Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Stem Cells, Platelet-Rich Plasma (PRP)), By Application, By End Use, By State, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國馬再生醫學市場的成長與趨勢

根據 Grand View Research, Inc. 的最新報告，美國馬再生醫學市場規模預計到 2030 年將達到 8,044 萬美元，預測期內複合年成長率為 8.31%。

推動市場成長的關鍵因素是運動和表演馬匹中肌肉骨骼損傷的盛行率不斷增加、再生醫學日益融入馬匹保險和護理模式、馬匹再生醫學的進步、寵物的人性化以及馬主消費者信心的不斷增強。

肌肉骨骼損傷，包括肌腱炎、韌帶斷裂、關節損傷和骨關節炎，在美國運動馬和表演馬中越來越常見。障礙賽、馬場馬術、繞桶賽和耐力賽等馬術運動的興起將馬匹推向了它們的身體極限，增加了軟組織和關節損傷以及其他相關併發症的風險。傳統治療方法（如非類固醇抗發炎藥和手術）通常會導致癒合不完全和較高的再次受傷率。再生療法，如富血小板血漿、幹細胞療法和 Prostride（一種自體蛋白溶液），因其能夠在細胞層面促進組織修復而越來越受歡迎。這些方法可以加快恢復速度，完全恢復馬的運動能力，並降低復發風險。

例如，間質幹細胞(MSC) 療法正擴大被用於治療懸韌帶撕脫傷，這是賽馬和跳馬運動員常見的損傷。研究表明，MSC 可以減輕炎症，改善肌腱纖維排列，從而實現更徹底的癒合。此類治療現已成為診所和就診醫院的標準做法，預示著由於損傷氾濫，市場將迎來強勁成長。

此外，獸醫再生醫學領域的科學創新正在推動市場發展。過去十年，分離、擴增和遞送幹細胞及生物藥品的技術變得更有效率、更經濟且可擴展。對細胞生物學、組織工程和生物材料的理解正在改善治療效果並擴大應用範圍。

根據 Equine Network LLC 在 2025 年 2 月發布的數據，注射金療法 (GOLDIC) 已成為治療方法馬匹骨關節炎 (OA) 和其他肌肉骨骼疾病的一種有前景的方法。透過將馬血與親水性金粒子一起孵育，可以獲得富含細胞激素和生長因子的血清，這些血清可以減少發炎並促進再生。在最近的一項研究中，GOLDIC 顯著改善了馬匹的跛行、儲存積液和腫脹症狀，其中許多馬匹在 3-6 個月後症狀消失。 GOLDIC 是一種創新治療方法，與傳統治療方法相比，它可以長期改善症狀，並可能獲得尋求更永續解決方案的獸醫和馬主的支持。憑藉其在減少發炎和促進組織再生方面的已證實的有效性，GOLDIC 可能會刺激馬匹領域採用更先進的骨科生物療法。這可能會增加對再生療法的需求，吸引更多投資，並影響馬匹各種肌肉骨骼和軟組織損傷的類似治療方法的發展。

美國馬再生醫學市場報告重點

  • 從產品來看，預計幹細胞領域將在2024年佔據最大的市場佔有率，達到61.75%。這歸功於幹細胞能夠促進組織再生，改善癒合質量，並減少關節、肌腱和韌帶損傷造成的疤痕形成。勃林格殷格翰收購全球幹細胞技術公司（Global Stem Cell Technology）等策略性投資，正將幹細胞定位為未來馬匹醫療保健的基石，進一步加速創新。
  • 根據應用情況，預計預測期內創傷和傷口護理領域將以最快的複合年成長率（8.65%）成長。這得益於受傷率的上升以及人們對馬匹健康意識的不斷提高。幹細胞、富血小板血漿、自體蛋白溶液、IRAP（免疫修復再生療法）和羊膜衍生產品等再生療法的創新顯著改善了傷口癒合，減少了疤痕形成。 Zaracil 先進的傷口護理配方等產品已展現出以科學為支撐的再生解決方案的潛力。如此快速的技術進步使創傷護理將成為未來幾年市場成長的關鍵驅動力。
  • 從最終用途來看，獸醫研究實驗室預計將成長最快，預測期內複合年成長率為8.75%，這得益於其在技術創新和臨床檢驗中的關鍵作用。他們的研究為再生療法的安全性和有效性提供了關鍵證據，並鼓勵更廣泛的臨床應用。透過推動組織修復和疾病預防領域的突破，這些實驗室正在塑造馬匹醫療保健的未來。
  • 到2024年，德克薩斯州將以16.61%的市佔率佔據市場佔有率主導地位。由於非侵入性治療需求的不斷成長、幹細胞和富血小板血漿療法的創新以及馬匹數量的龐大，預計該州的市場將快速成長。生技公司與獸醫診所之間的策略聯盟、收購和合作，例如Ardent Equine與Pegasus Orthobiologics的合作以及Vetirus Pharmaceuticals對Enso Discoveries的收購，正在進一步加強創新和治療開發，使佛羅裡達州成為該領域的領導者。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 北美馬再生醫學市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 補貼市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
    • 產業分析—波特五力分析
    • PESTEL分析
  • 2024年美國主要州馬匹數量估計
  • 法律規範
  • 美國馬業人口統計數據
    • 品種類型
    • 活動類型（例如運動）
    • 馬術產業事實與數據
  • 按產品進行價格分析
  • 產品平臺分析/臨床試驗分析
  • 保險覆蓋範圍分析

第4章美國馬再生醫學市場：產品、估計與趨勢分析

  • 細分儀表板
  • 美國馬再生醫學市場：產品差異分析，百萬美元，2024 年對比 2030 年
    • 幹細胞
    • 富血小板血漿（platelet-richplasma）
    • 其他

第5章美國馬再生醫學市場：應用預測與趨勢分析

  • 細分儀表板
  • 美國馬再生醫學市場：應用變化分析，百萬美元，2024 年和 2030 年
    • 整形外科
    • 創傷/創傷護理
    • 其他

第6章。美國馬再生醫學市場最終用途、估計和趨勢分析

  • 細分儀表板
  • 美國馬再生醫學市場：最終用途差異分析，百萬美元，2024 年對比 2030 年
    • 獸醫院/診所
    • 獸醫研究所
    • 其他

第7章美國馬再生醫學市場：國家估計與趨勢分析

  • 2024 年及 2030 年各州市場佔有率分析
  • 州立市場儀表板
  • 州市場概況
  • 2018-2030年市場規模、預測與趨勢分析
  • 美國
    • 德克薩斯
    • 加州
    • 佛羅裡達
    • 俄亥俄州
    • 奧克拉荷馬
    • 肯塔基州
    • 密蘇裡州
    • 賓州
    • 科羅拉多
    • 其他州

第8章 競爭態勢

  • 企業參與者的分類
  • 企業市場分析/熱圖分析
  • 公司簡介
    • Boehringer Ingelheim International GmbH
    • Zoetis
    • Dechra Pharmaceuticals Plc
    • Equine Amnio Solutions
    • VetStem, Inc.
    • Hilltop Bio
    • Equi-Stem LLC
    • Ardent Equine
    • Pronoia BIoTech
    • Medrego
    • AniCell BioTech
    • PetVivo Holdings, Inc.（Spyrng）
    • Arthrex Inc.
    • Contura Vet
    • Nucleus ProVets LLC
    • Enso Discoveries（Vetirus Pharmaceuticals）
    • Gallant Therapeutics
    • Astaria Global
    • Interpath Global（4CYTE）
    • American Regent, Inc.
  • 戰略地圖
    • 合併與收購
    • 夥伴關係和合作
    • 擴張
    • 產品發布
    • 其他
  • 其他主要參與企業名單
Product Code: GVR-4-68040-586-8

U.S. Equine Regenerative Medicine Market Growth & Trends:

The U.S. equine regenerative medicine market size is expected to reach USD 80.44 million by 2030, registering a CAGR of 8.31% over the forecast period, according to a new report by Grand View Research, Inc. The primary factors driving the market growth are the increasing prevalence of musculoskeletal injuries in sport & performance horses, the growing integration of regenerative medicine into equine insurance & practice models, advancements in equine regenerative medicine, and the growing pet humanization & equine owner willingness to spend.

Musculoskeletal injuries such as tendonitis, ligament tears, joint damage, and osteoarthritis are increasingly common among sport and performance horses in the U.S. These injuries significantly reduce performance ability, lead to prolonged recovery, and may end careers prematurely. The rise in competitive equestrian events like show jumping, dressage, barrel racing, and endurance racing pushes horses to their physical limits, increasing the risk of soft tissue, joint injuries and other related complications. Traditional therapies (like NSAIDs, surgery) often result in incomplete healing and high rates of re-injury. Regenerative therapies, including platelet-rich plasma (PRP), stem cell therapy, and Pro-Stride (autologous protein solution), are gaining traction due to their ability to enhance tissue repair at the cellular level. These approaches promote faster recovery and can restore the horse to full athletic performance, reducing the risk of recurrence.

An example is the increased adoption of mesenchymal stem cell (MSC) therapy to treat suspensory ligament desmitis, a common injury in racehorses and jumpers. Studies show MSCs can reduce inflammation and improve tendon fiber alignment, leading to more complete healing. Clinics and referral hospitals now offer such treatments as standard, indicating strong market growth based on injury prevalence.

Furthermore, scientific innovations in veterinary regenerative medicine propel the market forward. Over the past decade, techniques for isolating, expanding, and delivering stem cells or biologic agents have become more efficient, cost-effective, and scalable. Understanding cell biology, tissue engineering, and biomaterials has improved treatment outcomes and broadened applications.

As per data published in February 2025 by Equine Network LLC, injectable gold therapy (GOLDIC) is emerging as a promising treatment for equine osteoarthritis (OA) and other musculoskeletal conditions. By incubating the horse's blood with hydrophilic gold particles, the therapy produces a serum rich in cytokines and growth factors that help reduce inflammation and promote regeneration. In a recent study, GOLDIC significantly improved symptoms of lameness, joint effusion, and swelling in horses, with many becoming asymptomatic after three to six months. As an innovative therapy that offers long-term relief compared to traditional treatments, it could gain traction among veterinarians and horse owners looking for more sustainable solutions. With proven efficacy in reducing inflammation and enhancing tissue regeneration, GOLDIC might encourage the adoption of more advanced orthobiologic treatments in the equine sector. This could increase demand for regenerative therapies, attracting more investment and potentially influencing the development of similar treatments for various musculoskeletal and soft tissue injuries in horses.

U.S. Equine Regenerative Medicine Market Report Highlights:

  • Based on product, the stem cells segment held the largest market share of 61.75% in 2024. This can be attributed to its ability to promote proper tissue regeneration, improve healing quality, and reduce scar formation in joint, tendon, and ligament injuries. Strategic investments, such as Boehringer's acquisition of Global Stem Cell Technology, further accelerate innovation, positioning stem cells as a cornerstone of future equine healthcare.
  • Based on application, the trauma/ wound care segment is expected to grow at the fastest CAGR of 8.65% over the forecast period. This can be attributed to the rising incidence of injuries and increasing awareness of equine health. Innovations in regenerative therapies-such as stem cells, PRP, autologous protein solutions, IRAP, and amniotic-derived products-significantly improve healing and reduce wound scarring. Products like Zarasyl's advanced wound care formulations showcase the potential of science-backed regenerative solutions. This rapid technological advancement positions trauma care as a key driver of future market growth
  • By end use, the veterinary research institutes segment is expected to grow at the fastest CAGR of 8.75% during the forecast period. This can be owed to their pivotal role in innovation and clinical validation. Their research provides critical evidence supporting the safety and efficacy of regenerative treatments, encouraging wider clinical adoption. By driving breakthroughs in tissue repair and disease prevention, these institutes are shaping the future of equine healthcare.
  • The state of Texas dominated the market in 2024 with a share of 16.61%. It is expected to grow rapidly, driven by rising demand for non-invasive treatments and innovations in stem cell and PRP therapies, and the presence of a large horse population. Strategic partnerships, acquisitions, and collaborations between biotech companies and veterinary institutions, like Ardent Equine's partnership with Pegasus Orthobiologics and Vetirus Pharmaceuticals' acquisition of Enso Discoveries, further enhance innovation and therapy development, positioning Florida as a leader in the sector.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definition
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information/Data Analysis
  • 1.6. Market Formulation & Visualization
  • 1.7. Data Validation & Publishing
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
    • 1.8.2. Volume Price Analysis
    • 1.8.3. Global Market: CAGR Calculation
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Companion Animal Medicine Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Prevalence of Musculoskeletal Injuries in Sport and Performance Horses
      • 3.2.1.2. Increasing Integration of Regenerative Medicine into Equine Insurance and Practice Models
      • 3.2.1.3. Advancements in Equine Regenerative Medicine
      • 3.2.1.4. Growing Pet Humanization and Equine Owner Willingness to Spend
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost of Regenerative Therapies
      • 3.2.2.2. Regulatory Ambiguity and Lack of Standardization
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
    • 3.2.5. Industry Analysis - Porter's
      • 3.2.5.1. Bargaining power of the suppliers
      • 3.2.5.2. Bargaining power of the buyers
      • 3.2.5.3. Threats of substitution
      • 3.2.5.4. Threats from new entrants
      • 3.2.5.5. Competitive rivalry
    • 3.2.6. PESTEL Analysis
      • 3.2.6.1. Political landscape
      • 3.2.6.2. Economic and Social landscape
      • 3.2.6.3. Technological landscape
  • 3.3. Estimated Equine Population in U.S. Key States, 2024
  • 3.4. Regulatory Framework
  • 3.5. Equine Industry Demographics in the U.S.
    • 3.5.1. Type of Breeds
    • 3.5.2. Type of Activity (Sports & Others)
    • 3.5.3. Equestrian Industry Facts & Figures
  • 3.6. Pricing Analysis, by Product
  • 3.7. Product Pipeline Analysis/Clinical Trials Analysis
  • 3.8. Insurance Coverage Analysis

Chapter 4. U.S. Equine Regenerative Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Equine Regenerative Medicine Market: By Product Movement Analysis, USD Million, 2024 & 2030
    • 4.2.1. Stem Cells
      • 4.2.1.1. Stem Cells Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2. Platelet-Rich Plasma (PRP)
      • 4.2.2.1. Platelet-Rich Plasma (PRP) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.3. Others
      • 4.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Equine Regenerative Medicine Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Equine Regenerative Medicine Market: By Application Movement Analysis, USD Million, 2024 & 2030
    • 5.2.1. Orthopedics
      • 5.2.1.1. Orthopedics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. Trauma/ Wound Care
      • 5.2.2.1. Trauma/ Wound Care Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Others
      • 5.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Equine Regenerative Medicine Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Equine Regenerative Medicine Market: By End Use Movement Analysis, USD Million, 2024 & 2030
    • 6.2.1. Veterinary Hospitals/Clinics
      • 6.2.1.1. Veterinary Hospitals/Clinics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. Veterinary Research Institutes
      • 6.2.2.1. Veterinary Research Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Others
      • 6.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Equine Regenerative Medicine Market: State Estimates & Trend Analysis

  • 7.1. State Market Share Analysis, 2024 & 2030
  • 7.2. State Market Dashboard
  • 7.3. State Market Snapshot
  • 7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030:
  • 7.5. U.S.
    • 7.5.1. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Texas
      • 7.5.2.1. Texas market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. California
      • 7.5.3.1. California market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Florida
      • 7.5.4.1. Florida market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Ohio
      • 7.5.5.1. Ohio market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Oklahoma
      • 7.5.6.1. Oklahoma market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Kentucky
      • 7.5.7.1. Kentucky market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Missouri
      • 7.5.8.1. Missouri market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.9. Pennsylvania
      • 7.5.9.1. Pennsylvania market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.10. Colorado
      • 7.5.10.1. Colorado market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.11. Other States
      • 7.5.11.1. Other States market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Participant Categorization
  • 8.2. Company Market Position Analysis/ Heat Map Analysis
  • 8.3. Company Profile
    • 8.3.1. Boehringer Ingelheim International GmbH
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Zoetis
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Dechra Pharmaceuticals Plc
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Equine Amnio Solutions
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. VetStem, Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Hilltop Bio
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Equi-Stem LLC
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Ardent Equine
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Pronoia Biotech
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Medrego
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. AniCell BioTech
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. PetVivo Holdings, Inc. (Spyrng)
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Arthrex Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Contura Vet
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. Nucleus ProVets LLC
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
    • 8.3.16. Enso Discoveries (Vetirus Pharmaceuticals)
      • 8.3.16.1. Company overview
      • 8.3.16.2. Financial performance
      • 8.3.16.3. Product benchmarking
      • 8.3.16.4. Strategic initiatives
    • 8.3.17. Gallant Therapeutics
      • 8.3.17.1. Company overview
      • 8.3.17.2. Financial performance
      • 8.3.17.3. Product benchmarking
      • 8.3.17.4. Strategic initiatives
    • 8.3.18. Astaria Global
      • 8.3.18.1. Company overview
      • 8.3.18.2. Financial performance
      • 8.3.18.3. Product benchmarking
      • 8.3.18.4. Strategic initiatives
    • 8.3.19. Interpath Global (4CYTE)
      • 8.3.19.1. Company overview
      • 8.3.19.2. Financial performance
      • 8.3.19.3. Product benchmarking
      • 8.3.19.4. Strategic initiatives
    • 8.3.20. American Regent, Inc.
      • 8.3.20.1. Company overview
      • 8.3.20.2. Financial performance
      • 8.3.20.3. Product benchmarking
      • 8.3.20.4. Strategic initiatives
  • 8.4. Strategy Mapping
    • 8.4.1. Mergers & Acquisitions
    • 8.4.2. Partnerships & Collaborations
    • 8.4.3. Expansion
    • 8.4.4. Product launch
    • 8.4.5. Others
  • 8.5. List of other Key players

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Estimated Equine Population in U.S. key states, 2024.
  • Table 4. Pricing analysis by key products
  • Table 5. U.S. Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 6. U.S. Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 7. U.S. Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 8. U.S. Equine Regenerative Medicine Market, by State, 2018 - 2030 (USD Million)
  • Table 9. Texas Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 10. Texas Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 11. Texas Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 12. California Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 13. California Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 14. California Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15. Florida Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 16. Florida Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 17. Florida Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18. Ohio Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 19. Ohio Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 20. Ohio Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 21. Oklahoma Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 22. Oklahoma Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 23. Oklahoma Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 24. Kentucky Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 25. Kentucky Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 26. Kentucky Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 27. Missouri Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 28. Missouri Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 29. Missouri Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 30. Pennsylvania Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 31. Pennsylvania Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 32. Pennsylvania Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 33. Colorado Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 34. Colorado Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 35. Colorado Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 36. Other States Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 37. Other States Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 38. Other States Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 39. Company Overview
  • Table 40. Product Benchmarking
  • Table 41. Financial Performance
  • Table 42. Strategic Initiatives

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Equine Regenerative Medicine Market, Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 State Marketplace: Key Takeaways
  • Fig. 14 U.S. Equine Regenerative Medicine Market, for Product, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Equine Regenerative Medicine Market, for Stem Cells, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Equine Regenerative Medicine Market, for Platelet-Rich Plasma (PRP), 2018 - 2030 (USD Million)
  • Fig. 17 U.S. Equine Regenerative Medicine Market, for Others , 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Equine Regenerative Medicine Market, for Application, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. Equine Regenerative Medicine Market, for Orthopedics, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Equine Regenerative Medicine Market, for Trauma/Wound Care, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Equine Regenerative Medicine Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. Equine Regenerative Medicine Market, for End Use, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Equine Regenerative Medicine Market, for Veterinary Hospitals/Clinics, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Equine Regenerative Medicine Market, for Veterinary Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Equine Regenerative Medicine Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 26 State Outlook, 2024 & 2030
  • Fig. 27 Texas Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 28 California Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 29 Florida Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 30 Ohio Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 31 Oklahoma Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 32 Kentucky Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 33 Missouri Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 34 Pennsylvania Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 35 Colorado Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 36 Other States Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 37 Market participant categorization
  • Fig. 38 Heat map analysis
  • Fig. 39 Strategic Framework